Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines
Anticancer Research · 2024
DOI: 10.21873/anticanres.17345 ↗Kurz gefasst
Fachartikel in der Zeitschrift Anticancer Research, 2024. Verfasst von Samuel Angel und 4 weiteren Autor:innen. Beteiligte Einrichtung: College of Allopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, U.S.A. Hauptthemen laut MEDLINE: Dasatinib, Imatinib Mesylate, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Drug Synergism. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- College of Allopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, U.S.A.
- College of Allopathic Medicine, Nova Southeastern University, Ft. Lauderdale, FL, U.S.A. venk@nova.edu.
Zitieren
APA
Angel, S., Cowles, E., Costa, J., Ani, R. A., & Venkatachalam, K. V. (2024). Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines. Anticancer Research. https://doi.org/10.21873/anticanres.17345
Vancouver
Angel S, Cowles E, Costa J, Ani RA, Venkatachalam KV. Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines. Anticancer Research. 2024. doi:10.21873/anticanres.17345
BibTeX
@article{Angel2024,
author = {Angel, Samuel and Cowles, Emma and Costa, Jeams and Ani, Raad Al and Venkatachalam, Kallidaikurichi V},
title = {Synergistic Effects of Inecalcitol With Imatinib and Dasatinib on Chronic Myeloid Leukemia Cell Lines},
journal = {Anticancer Research},
year = {2024},
doi = {10.21873/anticanres.17345}
}
EUVIMED